Immunoassays – Products

Protein quantitation is an integral part of many protein biology workflows and a necessary step before commonly used techniques such as protein electrophoresis, western blotting, mass spectrometry and immunoassays.

Leica Microsystems and Cell Signaling Technology (CST) have announced a partnership to validate CST antibodies on the Cell DIVE multiplexed imaging solution.

The first of its kind, Rockland’s ModDetect™ Anti-PS Panel consists of specialty antibody reagents developed to detect phosphorothioate (PS) modifications independent of the sequence or location of the modification, making them useful for oligonucleotide therapeutic development, mRNA vaccine development, or research of genetic diseases or gene expression.

PerkinElmer’s Oxford Immunotec has announced the U.S. Food and Drug Administration has approved the use of the T-Cell Select™ reagent kit for the automation of its T-SPOT®.TB test workflow for in vitro diagnostic use by certified laboratories.

In quantifying therapeutic peptides and proteins in biological matrices, traditional ELISA-only based techniques can suffer from high variability, narrow dynamic range, problems with selectivity and typically cannot use internal standards.

The Signum™ range of surface-active polystyrene microplates from Porvair Sciences set a new high standard for reproducible binding of hydrophobic and hydrophilic proteins.

Beckman Coulter Life Sciences announces it has acquired ValitaCell Ltd, a biotechnology company that creates analytical products and technologies for the biopharmaceutical industry.

Bio-Rad Laboratories, Inc. has introduced a range of type 1 antibodies that inhibit the binding of evolocumab to its target, human proprotein convertase subtilisin/kexin type 9, a protein that has been shown to play a key role in the regulation of cholesterol levels.

Jackson ImmunoResearch announces a new addition to its range of products for scientists developing immunoassays for the serology and diagnostics markets.

Biotium has announced the release of new ExoBrite Antibody Conjugates. These antibodies were curated specifically for optimal detection of exosome markers CD9, CD63 and CD81 in isolated exosomes or exosome extracts with little to no background.